Leerink Partnrs Brokers Decrease Earnings Estimates for IDYA

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Equities researchers at Leerink Partnrs cut their FY2026 EPS estimates for shares of IDEAYA Biosciences in a research note issued to investors on Tuesday, September 9th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($4.05) per share for the year, down from their prior forecast of ($3.88). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ FY2027 earnings at ($4.04) EPS.

A number of other equities research analysts also recently weighed in on the stock. JMP Securities began coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set a “market outperform” rating and a $41.00 price objective for the company. Stephens reaffirmed an “overweight” rating and set a $45.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday. Barclays started coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They issued an “overweight” rating and a $40.00 target price for the company. Citizens Jmp started coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 target price for the company. Finally, The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a “hold” rating and set a $25.00 target price for the company in a research report on Thursday, July 10th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.75.

IDEAYA Biosciences Stock Up 0.9%

Shares of NASDAQ:IDYA opened at $24.93 on Thursday. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $37.80. The firm has a 50-day simple moving average of $23.89 and a 200 day simple moving average of $20.72. The company has a market cap of $2.18 billion, a PE ratio of -6.58 and a beta of 0.12.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analyst estimates of $3.48 million. During the same period in the previous year, the company posted ($0.68) earnings per share. The firm’s revenue was up NaN% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC boosted its holdings in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after acquiring an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after acquiring an additional 1,546 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $47,000. Signaturefd LLC boosted its holdings in shares of IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after acquiring an additional 2,271 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of IDEAYA Biosciences in the second quarter valued at approximately $61,000. 98.29% of the stock is currently owned by institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.